Amgen Patents Don't Advance Drug Science, Fed. Circ. Told
Sanofi SA and partner Regeneron Pharmaceuticals urged the Federal Circuit during oral arguments Tuesday to upend a validity finding for Amgen Inc. cholesterol-lowering drug patents, arguing the invention Amgen claims was...To view the full article, register now.
Already a subscriber? Click here to view full article